Unanswered questions

For reference: cystatin C · survodutide. I would like to define my thresholds before I have a result, for obvious reasons. I want a plan with explicit stopping rules,…

The specifics, since they change the answer: oral semaglutide · minus 20 °C. Somebody stated this to me confidently and I would like to check it before repeating it.…

I am comparing a supplier certificate against an independent result on the same lot. I keep seeing this stated as a fact with no explanation attached, and unexplained…

Setup, so nobody has to ask: retatrutide · mazdutide. Both of these get recommended confidently by different people, which suggests neither is obviously right. My…

I have three data points across nine months, which I hope is enough to see a trend. This is presented as though it settles something, and I am not convinced it does.…

For reference: tirzepatide · minus 80 °C · fourteen days. I am at the decision point and I would rather think it through than improvise. I would rather spend money on…

Concretely: SURMOUNT-1 · liraglutide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one. Can…

Details up front: a GLP-1 receptor agonist · 6.67 mg/mL. I would like to understand the steps well enough to explain them to someone else. I have access to a…

Conditions: semaglutide · 3.33 mg/mL. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan I write down,…

Concretely: ecnoglutide · Tianjin. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like the plan…

Concretely: 98.4% · tirzepatide · BCH. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like the…

My records go back to the first dose with dates, so I can reconstruct the timeline exactly. I keep seeing this stated as a fact with no explanation attached, and…

Stated plainly: purity figure · KP. I would like to set this up properly once, rather than adjust it repeatedly. My budget is real but not tight, and my tolerance for…

What I am working with: headache · a GLP-1 receptor agonist. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows,…

Numbers first: KP · QSC · Japan. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a defensible reason than a…

Conditions: CPC · Zhuhai Kerui Biotechnology. I would like the axes of comparison first and the recommendation second. I have tried the first option and it works; the…

Numbers first: 20 mg/mL · orforglipron. I have used one of these for a while and I am considering switching, which requires a reason. What I care about is…

The specifics, since they change the answer: GGPeps · Chinese Peptide Company. I am trying to choose between two options that are usually discussed as though only one…

For reference: identity confirmation by mass spectrometry · survodutide. I am at the decision point and I would rather think it through than improvise. I would rather…

What I am working with: aggregation · mazdutide · 2–8 °C. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I…

For reference: 96.4% · ecnoglutide · KP. I would like to define my thresholds before I have a result, for obvious reasons. I want a plan with explicit stopping rules,…

What I am working with: retatrutide · phosphate-buffered diluent. This is a procedural question rather than a theoretical one, and I would like the procedure rather…

What I am working with: dulaglutide · 2–8 °C. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched…

The case in front of me: survodutide · 3.33 mg/mL. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan I…